[1] Xu B，Xu GG，Guo Q，et al. Long term treatment of lamivudine in chronic hepatitis B patients with severe liver fibrosis-ten-year follow-up outcomes of NUCB 4006 trial. Chin J Infect Dis 2011，28（11）:656-661.
[2] Chang TT，Liaw YF，Wu SS，et al.Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology，2010，52（3）:886-893.
[3] Fink SA，Jacobson IM. Managing patients with hepatitis-B-related or hepatitis-C-related decompensated cirrhosis. Nat Rev Gastroenterol Hepatol，2011，8（5）:285-295.
[4] Zhang QQ，An X，Liu YH，et al. Long-term Nucleos（t）ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications:a meta-analysis.Virol J，2011，15（8）:72.
[5] Manolakopoulos S，Triantos C，Theodoropoulos J，et al. Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension. J Hepatol，2009，51（3）:468-474.
[6] Li CZ，Cheng LF，Li QS，et al. Antiviral therapy delays esophageal variceal bleeding in hepatitis B virus-related cirrhosis. World J Gastroenterol，2013，19（40）:6849-6856.
[7] Lok，AS. Hepatitis: Long-term therapy of chronic hepatitis B reverses cirrhosis. Nat Rev Gastroenterol Hepatol （advance online publication），29 January 2013；doi:10.1038/nrgastro. 2013.13.
[8] Perz JF，Armstrong GL，Farrington LA，et al.The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol，2006，45（4）: 529-538.
[9] Liaw YF，Leung N，Kao JH，et al. Asian-Pacific consensus statement on the management of chronic hepatitis B:a 2008 update. Hepatol Int，2008，2（3）:263-283.
[10] Iloeje UH，Yang HI，Su J，et al.Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology，2006，130（3）:678-686.
[11] Huo T，Wu JC，Hwang SJ，et al. Factors predictive of liver cirrhosis in patients with chronic hepatitis B:a multivariate analysis in a longitudinal study. Eur J Gastroenterol Hepatol， 2000，12（6）:687-693.
[12] Realdi G，Fattovich G，Hadziyannis S，et al.Survival and prognostic factors in 366 patients with compensated cirrhosis type B:a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis（EUROHEP）. J Hepatol， 1994，21（4）:656-666.
[13] Colin JF，Cazals-Hatem D，Loriot MA，et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology，1999，29（4）:1306-1310.
[14] Hsu YS，Chien RN，Yeh CT，et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology，2002，35（6）:1522-1527.
[15] Sánchez-Tapias JM， Costa J，Mas A. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology，2002，123（6）:1848-1856.
[16] Sumi H，Yokosuka O，Seki N，et al.Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology，2003，37（1）:19-26.
[17] Chu CJ，Hussain M，Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology，2002，122（7）:1756-1762.
[18] de Jongh FE，Janssen HL，de Man RA，et al. Survival and prognostic indicators in hepatitis B surface antigen-positivecirrhosis of the liver. Gastroenterology，1992，103（5）:1630-1635.
[19] Liaw YF，Chen JJ，Chen TJ. Acute exacerbation in patients with liver cirrhosis:a clinicopathological study. Liver，1990，10（3）:177-184.
[20] Chu CM， Liaw YF. Hepatitis B virus-related cirrhosis:natural history and treatment. Semin Liver Dis，2006，26（2）:142-152.
[21] Lefton HB，Rosa A，Cohen M. Diagnosis and epidemiology of cirrhosis. Med Clin N Am，2009，93（4）:787-799.
[22] Vallet-Pichard A，Mallet V，Costentin CE，et al. Treatment of HBV-related cirrhosis. Expert Rev Anti Infect Ther，2009，7（5）:527-535.
[23] Das K，Datta S，et al.Course of disease and survival after onset of decompensation in hepatitis B virus-related cirrhosis. Liver Int，2010，30（7）:1033-1042.
[24] Zoulim F，Radenne S，Ducerf C.Management of patients with decompensated hepatitis B virus associated [corrected] cirrhosis. Liver Transpl，2008，14（2）:S1-7.
[25] Chen CJ，Yang HI，Su J，et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA，2006，295（1）:65-73.
[26] Chen YC，Chu CM，Yeh CT，et al. Natural course following the onset of cirrhosis in patients with chronic hepatitis B:a long-term follow-up study. Hepatol Int，2007，1（1）:267-273.
[27] Fattovich G，Giustina G，Schalm SW，et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology，1995，21（1）:77-82.
[28] Fattovich G，Pantalena M，Zagni I，et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis:a cohort study of 297 patients. Am J Gastroenterol，2002，97（11）:2886-2895.
[29]中华医学会肝病学分会. 慢性乙型肝炎防治指南. 中国病毒病杂志，2011，1（1）:9-23.
[30] Colli A，Fraquelli M，Andreoletti M，et al.Severe liver fibrosis or cirrhosis:accuracy of US for detection-analysis of 300 case. Radiology，2003，227（1）:89-94.
[31] 郑荣琴， 黄冬梅， 张波等. 超声、CT及MRI诊断肝硬化的比较. 世界华人消化杂志，2005，13（8）:993-996.
[32] Bedossa P，Dargere D，Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology，2003，38（6）:1449-1457.
[33] Min-De Zeng，Lun-Gen Lu，Yi-Min Mao，et al. Prediction of Significant Fibrosis in HBeAg-Positive Patients With Chronic Hepatitis B by a Noninvasive Model. Hepatology，2005，42（6）: 1437-1445.
[34] 肝脏硬度评估小组. 瞬时弹性成像技术诊断肝纤维化专家意见. 中华肝脏病杂志，2013，2l（6）:420-424.
[35] Poynard T，Munteanu M，Imbert-Bismut F，et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem，2004， 50（8）:1344-1355.
[36] Poynard T，McHutchison J，Manns M，et al. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin.Hepatology，2003，38（2）: 481-492.
[37] Poynard T，Ngo Y，Munteanu M，et al. Noninvasive markers of hepatic fibrosis in chronic hepatitis B. Curr Hepat Rep， 2011，10（2）:87-97.
[38] Bartres C，Lens S. Elastography of the liver（Fibroscan） in hepatology. Rev Esp Enferm Dig，2013，105（4）:235.
[39] Janssens F，de Suray N，Piessevaux H， et al. Can transient elastography replace liver histology for determination of advanced fibrosis in alcoholic patients:A real-life study. Clin Gastroenterol，2010，44（8）:575-582.
[40] Castera L. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat，2009，16（5）:300-314.
[41] Bonnard P，Sombié R，Lescure FX，et al. Comparison of elastography，serum marker scores，and histology for the assessment of liver fibrosis in hepatitis B virus（HBV）-infected patients in Burkina Faso. Trop Med Hyg，2010，82（3）:454-458.
[42] Lau H，Man K，Fan ST，et al. Evaluation of preoperative hepatic function in patients with hepatocellular carcinoma undergoing hepatectomy. Br J Surg，1997，84（9）:1255-1259.
[43] Chen X，Zhang HB，Li ZQ，et al. Indocyanine green clearance in evaluating the recovery of liver reserve function after super selective transarterial chemoembolization. Hepatobiliary Pancreat Dis Int，2013，12（6）:656-660.
[44] Durand F，Valla D.Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol，2005，42 Suppl（1）:S100-107.
[45] Schuppan D，Afdhal NH. Liver cirrhosis.Lancet，2008，371（9615）:838-851.
[46] Arvaniti V，D'Amico G，Fede G，Manousou P，et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology， 2010，139（4）:1246-56， 1256.e1-5.
[47] 中国抗癌协会肝癌专业委员会. 原发性肝癌规范化诊治专家共识. 临床肿瘤学杂志，2009，14（3）:259-269.
[48] Fung SK，Lok AS. Management of patients with hepatitis B virus-induced cirrhosis. J Hepatol，2005，42 Suppl（1）:S54-64.
[49] Fontana RJ， Hann HW，Perrillo RP，et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology，2002，123（3）:719-727.
[50] Chien RN，Lin CH，Liaw YF. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol，2003,38（3）:322-327.
[51] Tsubota A, Arase Y, Suzuki Y, et al. Lamivudine mono therapy for spontaneous severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol，2005，20（3）:426–432.
[52] Perrillo R，Tamburro C，Regenstein F，et al. Low-dose，titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology， 1995，109（3）:908-916.
[53] Hoofnagle JH，DiBisceglie AM，Waggoner JG，et al. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology，1993，104（4）:1116-1121.
[54] Honkoop P，Niesters HG，de Man RA，et al. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol，1997，26（6）:1393-1395.
[55] Lai CJ，Terrault NA. Antiviral therapy in patients with chronic hepatitis B and cirrhosis. Gastroenterol Clin North Am，2004，33（3）:629-654.
[56] Alberti A，Caporaso N. HBV therapy:Guidelines and open issues. Digest Liver Dis，2011，43（1）:S57-S63.
[57] van Zonneveld M，Honkoop P，Hansen BE，et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology，2004，39（3）:804-810.
[58] Liaw YF，Sung JJ，Chow WC，et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med，2004，351（15）:1521-1531.
[59] Schiff E，Simsek H，Lee WM，et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol，2008，103（11）:2776-2783.
[60] Villeneuve JP，Condreay LD，Willems B，et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology，2000，31（1）:207-210.
[61] Fontana RJ，Keeffe EB，Carey W，et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl， 2002，8（5）:433-439.
[62] Hann HW，Fontana RJ，Wright T，et al. A United States compassionate use study of lamivudine treatment in non transplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl，2003，9（1）:49-56.
[63] Yao FY，Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol，2000，33（2）:301-307.
[64] Kapoor D，Guptan RC，Wakil SM，et al.Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol，2000，33（2）:308-312.
[65] Manolakopoulos S，Karatapanis S，Elefsiniotis J，et al. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg-negative chronic hepatitis B. Am J Gastroenterol，2004，99（1）:57-63.
[66] Bae SH，Yoon SK，Choi JY，et al. Timing of lamivudine administration according to Child class in patients with decompensated cirrhosis. J Gastroenterol Hepatol，2005，20（10）:1527-1532.
[67] Perrillo RP，Wright T，Rakela J，et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology，2001，33（2）:424-432.
[68] Zoulim F，Locarnini S. Hepatitis B virus resistance to nucleos（t）ide analogues. Gastroenterology，2009，137（5）:1593-608.
[69] Schiff ER，Lai CL，Hadziyannis S，et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology，2003，38（6）:1419-1427.
[70] Schiff E，Lai CL，Hadziyannis S，et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B:final long-term results. Liver Transpl，2007，13（3）:349-360.
[71] Lampertico P. Partial virological response to nucleos（t）ide analogues in nave patients with chronic hepatitis B:From guidelines to field practice. J Hepatol，2009，50（4）:644-647.
[72] Shim JH，Lee HC，Kim KM，et al. Efficacy of entecavir in treatment-nave patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol，2010，52（2）:176-182.
（收稿：
通讯作者：茅益民，上海交通大学医学院附属仁济医院，E-mail:maoym11968@163.com);尤红,首都医科大学附属友谊医院，E-mail:youhong30@sina.com;贾继东,首都医科大学附属友谊医院，E-mail:jiamd@263.net
基金项目：本文受科技部十二五重大专项课题基金资助（课题编号：2012ZX09303001和2013ZX10002004） |
